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ABSTRACT
The sex steroid 17b-estradiol (17b-E2) has a broad range of actions, including effects on calcium and bone
metabolism. This study with 3-month-old Brown Norway rats was designed to investigate the role of 17b-E2 in the
regulation of calcium homeostasis. Rats were divided in four groups, sham-operated, ovariectomized (OVX), and
OVX supplemented with either a 0.025-mg or 0.05-mg 17b-E2 pellet implanted subcutaneously. After 4 weeks, in
none of the groups was serum calcium, phosphate, or parathyroid hormone altered compared with the sham
group, while only in the OVX rats was a significant reduction in urinary calcium found. Bone mineral density and
osteocalcin were modified, as can be expected after OVX and 17b-E2 supplementation. OVX resulted in a non-
significant increase in serum 1,25-dihydroxyvitamin D3 (1,25(OH)2D3). Supplementation with either one of the
17b-E2 dosages resulted in an 80% reduction of 1,25(OH)2D3 and only a 20% reduction in 25-hydroxyvitamin D3
levels. OVX, as well as supplementation with 17b-E2, did not affect serum levels of vitamin D binding protein. As
a consequence, the estimated free 1,25(OH)2D3 levels were also significantly decreased in the 17b-E2–supplemented
group compared with the sham and OVX groups. Next, the consequences for intestinal calcium absorption were
analyzed by the in situ intestinal loop technique. Although the 1,25(OH)2D3 serum level was increased, OVX
resulted in a significant decrease in intestinal calcium absorption in the duodenum. Despite the strongly reduced
1,25(OH)2D3 levels (18.1 ± 2.1 and 16.4 ± 2.2 pmol/l compared with 143.5 ± 29 pmol/l for the OVX group), the
OVX-induced decrease in calcium absorption could partially be restored by supplementation with either 0.025 mg
or 0.05 mg of 17b-E2. None of the treatments resulted in a significant change in calcium handling in the jejunum,
although the trends were similar as those observed in the duodenum. 17b-E2 did not change the VDR levels in both
the intestine and the kidney. In conclusion, the present study demonstrates that 17b-E2 is positively involved in
intestinal calcium absorption, and the data strengthen the assertion that 17b-E2 exerts this effect independent of
1,25(OH)2D3. In general, 17b-E2 not only affects bone turnover but also calcium homeostasis via an effect on
intestinal calcium absorption. (J Bone Miner Res 1999;14:57–64)
INTRODUCTION
17b-ESTRADIOL (17b-E2) has evolved from a steroid hor-mone involved in reproduction into a pleiotropic hor-
mone. Its receptor has been identified in multiple tissues
not considered classical targets, including the central ner-
vous system, endocrine glands, skin, myocardium, aorta,
kidney, intestine, and bone.(1–3) Therefore, 17b-E2 should
be considered to be more than a sex steroid.
The significance of estradiol for bone is perfectly illus-
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trated by the drop in bone mineral density (BMD) after the
menopause and the low bone mass observed in the estrogen
receptor as well as the aromatase-deficient individuals.(4,5)
During growth (modeling bone), estradiol is involved in
closure of the growth plate. In remodeling bone, estradiol is
involved in the maintenance of the balance between bone
resorption and bone formation,(6,7) thereby affecting BMD
and bone architecture.(8–11) These effects can be direct and/
or indirect via regulation of and/or interaction with other
factors influencing bone metabolism, e.g., parathyroid hor-
mone (PTH) and insulin-like growth factor I.(12–17)
Menopause is associated with decreased calcium absorp-
tion,(18) which can be normalized by 17b-E2 supplementa-
tion.(19,20) A positive regulation of intestinal calcium ab-
sorption by estradiol has been suggested by Arjmandi et
al.(21) Therefore, modulation of intestinal calcium absorp-
tion could be a target for estradiol and selective estrogen
receptor modulators in postmenopausal osteoporosis. How-
ever, a study by Hope et al. demonstrated an increase in
intestinal calcium transport in rats after ovariectomy
(OVX).(22) So far, data on direct measurements of calcium
movements across the duodenal mucosa in relation to es-
tradiol status are lacking.
The present study was designed to provide knowledge on
the role of estradiol in intestinal calcium absorption and
bone metabolism. This was examined by using OVX rats
supplemented with estradiol or not. The effect on calcium
absorption was measured with the in situ loop tech-
nique.(23) In addition, the relationship of estradiol with the
classical calciotropic hormones, 1,25-dihydroxyvitamin D3
(1,25(OH)2D3) and PTH and the effects on BMD and renal
calcium handling were assessed.
MATERIALS AND METHODS
Animals
Experiment 1: Thirty female Brown Norway rats were
divided into four groups to evaluate effects of 17b-E2 on
intestinal calcium transport and calcium and bone metabo-
lism parameters. Eight rats were sham operated (sham
group) and 22 rats were ovariectomized (OVX group). In
six OVX rats, a 0.025-mg 17b-E2 60-day release pellet and
in eight OVX rats a 0.05-mg 17b-E2 pellet (Innovative Re-
search of America, Toledo, OH, U.S.A.) was subcutane-
ously implanted in the neck. These pellets are formulated to
release a constant amount of 17b-E2 for up to 60 days when
implanted subcutaneously.
Experiment 2: Thirty-six rats were equally divided into
three groups of 12 rats each to study the effects of 17b-E2
on intestinal and renal vitamin D receptor (VDR) and cal-
bindin 28K content. In addition, effects on vitamin D–bind-
ing protein (DBP) and BMD were examined. Rats were
sham operated, ovariectomized, or ovariectomized with im-
plantation of a 0.05-mg 17b-E2 pellet.
In both experiments, deionized water and a standard diet
containing 0.7% calcium, 0.5% phosphorus, and 1.5 U of
vitamin D3/g (Hopefarm, Woerden, The Netherlands) were
available ad libitum to the sham-operated up. The treated
groups (OVX ± 17b-E2) were fed the same amount of food
per gram of body weight as the sham-operated group to
minimize differences in body weight.
After 3 weeks, the rats were put in metabolic cages and
overnight nonfasting urine was collected. After 4 weeks, all
rats were bled under ether anesthesia from the abdominal
aorta, and several parameters for calcium and bone me-
tabolism were measured. In the second experiment, intes-
tines and kidneys were collected to quantitate calbindin
28K and/or VDR content, and in serum, DBP was mea-
sured. The study was approved by the committee for use of
laboratory animals of the Erasmus University, Rotterdam.
Analytical procedures
Serum calcium, inorganic phosphate, alkaline phospha-
tase, total protein, urinary calcium, inorganic phosphate,
and creatinine were analyzed with standard methods. Os-
teocalcin was determined by a rat-specific radioimmunoas-
say (RIA).(24) Intact PTH was measured using a rat-specific
immunoradiometric method (Nichols Institute, San Clem-
ente, CA, U.S.A.). 1,25(OH)2D3 was measured by immu-
noextraction followed by quantitation by 125I-RIA (IDS,
Boldon, U.K.). Concentrations of 25-hydroxyvitamin D3
(25(OH)D3) were measured by RIA (Incstar Corp., Still-
water, MN, U.S.A.). Serum concentrations of DBP were
measured by radial immunodiffusion.(25) The ratio (×103)
of the molar concentrations of 1,25(OH)2D3 and DBP was
used as an estimate of free hormone concentration.(26) Se-
rum 17b-E2 was measured by an extraction procedure using
diethyl ether followed by RIA (DPC, Los Angeles, CA,
U.S.A.). The BMD of the right femur was measured ex vivo
using dual-energy X-ray absorptiometry (DPX-L; Lunar
Corp., Madison, WI, U.S.A.). Femora were placed under
2.5 cm of water using the high-resolution mode, as recom-
mended by the manufacturer. The Lunar Small Animal
Software Package Ic was used for analysis. The coefficient
of variation, evaluated by scanning the same femur 10 times
over a short period of time, was 1.1%.
Calcium transport measurement
45CaCl2 (1.61 mCi/mg of Ca) was obtained from Amer-
sham (Arlington Heights, IL, U.S.A.) and [1,2-3H]
polyethyleneglycol (PEG; MW 4000, 0.45 mCi/g) was ob-
tained from DuPont-NEN (Boston, MA, U.S.A.).
Four weeks after operation, calcium transport measure-
ments were performed under ether anesthesia by the in situ
loop technique after overnight fasting.(23) Shortly thereaf-
ter, a midline incision was made in the bile duct and two
intestinal segments were ligated. The first segment (duode-
num) was from 1 cm distal to the pylorus to 2 cm distal to
Treitz’s ligament. The second part encompassed jejunum
and was from 13–23 cm distal to the pylorus. Transport
medium (750 ml), prewarmed to 37°C, was injected with a
25-gauge needle in each ligated segment. The transport me-
dium contained 164 mM NaCl, 0.88 mM 45CaCl2 (610–680
dpm/nmol), and [1,2-3H]PEG (720 dpm/nmol). Following
an equilibration period of 5 minutes, a 50-ml sample from
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the luminal content was taken by means of a transmural
puncture to calculate the initial intraluminal solvent vol-
ume, 45Ca and 40Ca content. Twice 10 ml of the sample was
dissolved in 5 ml of scintillation fluid (Packard, Downers
Grove, IL, U.S.A.), and 45Ca and 3H values were deter-
mined in a Packard 2650 Tricarb scintillation counter. 40Ca
was measured by a calcium kit (Sigma Chemical Co., St.
Louis, MO, U.S.A.). Duodenal and jejunal loops were re-
moved after 25 and 30 minutes, respectively. The length
was measured, and two samples of 20 ml were taken from
the luminal content for determination of 45Ca and 3H ra-
dioactivity. Also, the 40Ca concentration in two samples of
10 ml was determined in the luminal fluid. The lumen was
flushed with 500 ml of NaCl 0.9% to determine the recovery
of 3H-PEG in order to assess whether transport medium
had leaked from the intestinal lumen to the abdominal cav-
ity. Intestinal calcium transport was calculated via the fol-
lowing formulas.
1. Ca-influx (nmol of Ca per cm of intestine per 30 min-
utes): defined as the unidirectional movement of calcium
from intestinal lumen into tissue (mean value over the
period studied)
Ca-influx 4 [Vi(
45Cai) − Vf(
45Caf)]/SA × L
where Vi (initial volume in ml) refers to the injected
solvent volume corrected for dilution by residual endog-
enous luminal fluid at t0 on the basis of the change in
PEG concentration in the previous 5 minutes. Vf (final
volume in ml) refers to solvent volume left at the end of
the absorption period (t30). This parameter is calculated
as the product of the ratio of PEG concentration at t0
versus t30 and Vi.
45Cai and
45Caf (dpm per ml of intra-
luminal fluid) refer to initial and final 45Ca concentration
at t0 and t30, respectively. SA (dpm per nmol Ca) refers
to the specific activity of Ca. L refers to the length of the
ligated intestinal segment.
2. Net Ca absorption (nmol Ca per cm of intestine per 30
minutes): defined as the total amount of Ca absorbed
from the intestinal lumen
Net Ca abs 4 40CaiVi −
40CafVf
where 40Cai and
40Caf (nmol per ml of intraluminal fluid)
refer to the initial and final 40Ca concentration.
3. Ca-efflux (nmol of Ca per cm of intestine per 30 min-
utes): defined as unidirectional movement of calcium
that enters the intestinal lumen from the tissue:
Ca-efflux 4 Ca-influx − Net Ca abs
In the calculations, it is assumed that 45Ca-efflux is neg-
ligible.
VDR analysis
Nuclear extracts were prepared as described previ-
ously.(27) Briefly, 20 cm of proximal small intestines was
excised and flushed with 20 ml of ice-cold TED-saline (50
mM Tris-HCl, pH 7.4, 1.5 mM EDTA, 5 mM DTT, 0.2 mM
phenylmethylsulfonyl fluoride [PMSF], 10 mg/ml TPCK, 1
mg/ml leupeptin, and 1 mg/ml pepstatin). Scraped mucosa
and kidneys were washed three times in TED-saline for 10
minutes at 3000g. Mucosa and kidneys were homogenized
in 10 vol (w/v) KTED-300 (TED, 300 mM KCl) in a glass-
Teflon homogenizer and polytron, respectively. Homog-
enates were centrifuged for 1 h at 100,000g, and extracts
were stored at −80°C. The concentration of VDR was mea-
sured by a VDR-specific ELISA.(28)
Calbindin 28K quantitation
Kidneys were homogenized (20% w/v) in phosphate-
buffered saline in the presence of enzyme inhibitors (10−4
M PMSF, 10−4 M TPCK) using a polytron. Homogenates
were centrifuged at 38,000g. Supernatant solution was
stored at −80°C and analyzed as described previously.(29)
Statistical analysis
Data analysis involved estimation of the means, SDs,
standard errors, and one-way analysis of variance. p < 0.05
was considered statistically significant.
RESULTS
General measurements
Table 1 shows that OVX and 17b-E2 suppletion resulted
in the anticipated phenotypes. OVX rats had reduced
TABLE 1. EFFECTS OF OVX AND 0.025 MG 17b-ESTRADIOL (OVX + E2L) OR 0.05 MG
17b-ESTRADIOL (OVX + E2H) IN RATS 4 WEEKS AFTER OPERATION
SHAM
(n = 8)
OVX
(n = 8)
OVX + E2L
(n = 6)
OVX + E2H
(n = 8)
Body weight
beginning (g) 139 ± 3.9 140 ± 3.4 142 ± 1.4 140 ± 2.1
final (g) 138 ± 4.0 143 ± 3.3 135 ± 2.1 131 ± 2.7*
Organ weight
uterus (g) 0.327 ± 0.036 0.082 ± 0.005† 0.601 ± 0.028†‡ 0.617 ± 0.027†‡
spleen 0.358 ± 0.01 0.407 ± 0.01 ND 0.309 ± 0.01
Serum
17b-E2 (pmol/l) 16.1 ± 4.6 3.0 ± 1.5
† 21.2 ± 4.0* 41.5 ± 4.6†‡
Data are presented as means ± SEM; *p < 0.01 vs. OVX; †p < 0.001 vs. sham; ‡p < 0.001 vs. OVX;
ND, not determined.
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uterus weights and increased spleen weight. Although se-
rum 17b-E2 levels in OVX + 0.025 mg 17b-E2 rats were
similar as in sham-operated rats, uterus weights were sig-
nificantly increased. Supplementation with the highest 17b-
E2 dose resulted in a similar increase in uterus weight as in
the OVX + 0.025 mg 17b-E2 group, while serum 17b-E2
levels in the OVX + 0.05 mg 17b-E2 rats were higher, i.e., at
estrus level. Body weights in the treated groups were not
significantly different from the sham-operated rats, but in
the E2H group they were significantly lower compared with
the OVX rats.
Calcium and bone metabolism
No significant differences between 17b-E2–treated
groups and sham-operated rats in serum calcium and inor-
ganic phosphate levels were detected, while serum inor-
ganic phosphate levels were significantly lower compared
with OVX rats.
OVX resulted in a significant reduction in BMD, while
17b-E2 treatment restored BMD and even resulted in an
increased BMD (Table 2). Effects of OVX and 17b-E2
treatment on bone turnover are also reflected by changes in
serum osteocalcin levels. In OVX rats, serum osteocalcin
levels were elevated while treatment with 17b-E2 signifi-
cantly suppressed this increase (Table 2). Serum alkaline
phosphatase levels were significantly reduced in both 17b-
E2–replete groups compared with sham-operated as well as
OVX rats (Table 2).
Vitamin D
Serum total calcitriol levels were not significantly el-
evated (by about 30%) in the OVX rats. In the 17b-E2–
replete rats, serum total 1,25(OH)2D3 levels were signifi-
cantly decreased by more than 80% in comparison with
sham-operated rats. Serum 25(OH)D3 levels were only re-
duced by about 20% in 17b-E2–replete rats, while serum
PTH levels were similar in all groups (Table 2). To address
whether the major changes observed in total 1,25(OH)2D3
are reflected in the free levels of 1,25(OH)2D3, in the sec-
ond experiment the DBP levels were determined. As can be
seen in Table 3, the serum DBP levels were not affected by
OVX or 17b-E2 treatment. As a consequence, also the free
1,25(OH)2D3 levels are strongly reduced after OVX with
17b-E2 suppletion.
Calcium transport
Despite normal or even somewhat raised serum
1,25(OH)2D3 levels in OVX rats, calcium influx in the du-
odenum was significantly reduced by 45% compared with
the sham-group (Fig. 1A). Calcium efflux was increased,
although not significantly, by 41% in the OVX group.
These opposite changes in calcium influx and calcium efflux
resulted in a significantly decreased net calcium absorption
in duodenum following OVX (Fig. 1A).
The calcium influx was significantly reduced in both 17b-
E2–replete groups compared with sham-operated rats (Fig.
1). Although the 17b-E2–replete rats had an ~ 90% lower
serum 1,25(OH)2D3 level than OVX rats, calcium influx
was even somewhat higher than in OVX rats. The calcium
efflux was not changed in the 17b-E2–replete rats compared
with the sham group, and therefore calcium efflux was less
than in the OVX group. Taken together, 17b-E2 treatment
partially restored net calcium absorption and was not sig-
nificantly different from the sham group, despite a strongly
reduced 1,25(OH)2D3 concentration (Fig. 1A).
In the jejunum, no significant differences between the
groups were observed (Fig. 1B). However, similar trends
were observed as in the duodenum. Again in 17b-E2–
replete rats, despite low serum 1,25(OH)2D3 levels, calcium
influx was higher and calcium efflux was lower, resulting in
an apparently higher net calcium absorption compared with
OVX rats.
Overnight nonfasting urinary calcium excretion, which
TABLE 2. EFFECTS OF OVX AND 0.025 MG 17b-ESTRADIOL (OVX + E2L) OR 0.05 MG 17b-ESTRADIOL (OVX + E2H)
ON CALCIUM AND BONE METABOLISM PARAMETERS 4 WEEKS AFTER OPERATION
Sham
(n = 8)*
OVX
(n = 8)*
OVX + E2L
(n = 6)*
OVX + E2H
(n = 8)*
Serum
calcium (mmol/l) 2.11 ± 0.03 2.15 ± 0.07 2.17 ± 0.27 2.18 ± 0.02
phosphate (mmol/l) 2.99 ± 0.07 3.18 ± 0.14 2.67 ± 0.13† 2.65 ± 0.06†
alkaline phosphatase (U/ml) 42.6 ± 1.4 47.7 ± 2.8 32.8 ± 1.7‡§ 33.4 ± 1.0‡§
osteocalcin (mg/l) 514.4 ± 37.8 739.8 ± 59.9\ 473.7 ± 26.5¶ 392.3 ± 16.1§#
25(OH)D3 (nmol/l) 72.7 ± 2.5 71.3 ± 1.9 56.0 ± 2.8
‡§ 58.9 ± 2.5‡§
1,25(OH)2D3 (pmol/l) 105.4 ± 21.5 143.5 ± 29.0 18.1 ± 2.1
‡§ 16.4 ± 2.2‡§
PTH (ng/l) 41.9 ± 11.2 53.1 ± 12.2 58.5 ± 10.8 56.6 ± 6.9
Urine
calcium/creatinine 0.80 ± 0.15 0.48 ± 0.05# 0.73 ± 0.03¶ 0.98 ± 0.06§
BMD (g/cm2) 0.183 ± 0.022 0.174 ± 0.012 ND 0.195 ± 0.026
Urinary calcium excretion was measured 3 weeks after operation.
* Except for BMD measurements, n 4 12/group.
Data are presented as means ± SEM. †p < 0.05 vs. OVX; ‡p < 0.001 vs. sham; §p < 0.001 vs. OVX; \p < 0.01 vs. sham; ¶p < 0.01 vs.
OVX; #p < 0.05 vs. sham.
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indirectly reflects total intestinal calcium absorption, was
significantly lower in OVX rats compared with sham-
operated and 17b-E2–replete rats. No significant differ-
ences in urinary calcium excretion were found between
17b-E2–replete and sham-operated rats (Table 2).
Intestinal VDR and renal VDR and calbindin
28K content
A possible mechanism by which 17b-E2 affects intestinal
calcium absorption is by facilitating 1,25(OH)2D3 action via
an increase in its receptor number, thereby potentially com-
pensating for the reduction in 1,25(OH)2D3 levels. There-
fore, nuclear extracts of intestines of sham-operated, OVX
and OVX + 0.05 mg 17b-E2–replete rats were prepared and
the VDR content was established. Neither OVX nor 17b-
E2 treatment resulted in a significant change in intestinal
VDR number (Table 3). In addition, in the kidney, the
VDR number was not different among sham, OVX, and
17b-E2–replete rats (Table 3). In addition, we measured in
the kidneys whether the alterations in renal calcium excre-
tion could be related to changes in calbindin 28K levels. As
shown in Table 3, neither OVX nor 17b-E2 treatment modi-
fied the renal calbindin 28K levels.
DISCUSSION
This study shows that 17b-E2 has important effects on
intestinal calcium absorption. This conclusion is based on
the following observations. First, in the present study, cal-
cium influx from the duodenum of OVX rats was strongly
reduced, although serum 1,25(OH)2D3 levels were even
slightly (about 30%) higher than in the sham rats. Although
not significant, calcium efflux was even higher in 17b-E2–
deficient rats, and therefore net calcium absorption was
significantly reduced in OVX rats. This supports previous
findings that menopause is associated with decreased intes-
tinal calcium absorption.(18) Furthermore, it is consistent
with the observation that in postmenopausal women estro-
gen supplementation normalizes intestinal calcium trans-
port.(20,30) Second, in both 17b-E2–replete groups, serum
1,25(OH)2D3 levels were reduced by ~ 90% compared with
the OVX group, which would have implicated an even fur-
ther decrease in intestinal calcium transport.(31,32) How-
ever, in contrast to the OVX group, in both 17b-E2–replete
groups, net calcium absorption in the duodenum was not
significantly different from the sham group. These direct
calcium movement measurements support the calcium ab-
sorption data derived from food-intake studies.(21) Finally,
an indirect measurement, nocturnal nonfasting urinary cal-
cium excretion, which can be considered to reflect intestinal
calcium absorption in rats eating during the night, was sig-
nificantly higher in the 17b-E2–replete groups compared
with the OVX rats.
The effect of 17b-E2 on intestinal calcium absorption can
be exerted by modulating 1,25(OH)2D3 action or indepen-
dent of 1,25(OH)2D3. The significantly reduced calcium ab-
sorption in the 17b-E2–deficient OVX group, while the
1,25(OH)2D3 levels are increased, suggest that in the ab-
sence of 17b-E2 the intestine is desensitized for the action
of 1,25(OH)2D3. In other words, 17b-E2 sensitizes the in-
testine for the action of 1,25(OH)2D3. However, in case of
a sensitizing action, this must be independent of changes in
the VDR number in the intestine (Table 3). The calcium
absorption in the 17b-E2 supplemented groups, while
1,25(OH)2D3 levels are strongly reduced (80–90% lower
than in the sham and OVX groups, respectively) shows that
17b-E2 has a direct effect on intestinal calcium absorption
independent of 1,25(OH)2D3 level. Our observations on
the VDR are consistent with the recent data from Kinyamu
et al., who found no change in intestinal VDR level, while
intestinal calcium absorption was decreased in postmeno-
pausal women compared with premenopausal women.(33)
However, previously Ebeling et al. have reported that the
decreased intestinal calcium absorption of postmenopausal
women could be attributed to a decline in intestinal VDR
number, but the number of elderly subjects in this study was
small.(34) Although an interaction between 17b-E2 and
1,25(OH)2D3 can not be conclusively excluded, our data
suggest a 1,25(OH)2D3-independent effect of 17b-E2 on in-
testinal calcium absorption. This is supported by the obser-
vations that 17b-E2 stimulates calcium uptake in cultured
rat duodenal enterocytes.(35) The 17b-E2 effects on intesti-
nal calcium absorption can be due to direct effects on the
TABLE 3. EFFECTS OF OVX AND 0.05 MG 17b-ESTRADIOL (OVX + E2H) ON VITAMIN D
BINDING PROTEIN, INTESTINAL VDR, AND RENAL VDR AND CALBINDIN 28K CONTENT
4 WEEKS AFTER OPERATION
Sham
(n = 12)
OVX
(n = 12)
OVX + E2H
(n = 12)
1,25(OH)2D3 (pmol/l) 87.6 ± 15.8 111.7 ± 13.9 28.9 ± 7.9*
DBP (mmol/l) 7.3 ± 0.1 7.7 ± 0.1 7.3 ± 0.1
Free 1,25(OH)2D3 (index × 10
−3) 12.3 ± 2.3 14.6 ± 1.9 4.0 ± 1.2*
Intestine
VDR (fmol/mg protein) 190.9 ± 48.0 193.9 ± 32.1 217.3 ± 38.7
Kidneys
VDR (fmol/mg protein) 18.2 ± 2.5 19.6 ± 2.2 22.2 ± 8.1
CaBP28K (mg/mg protein) 5.16 ± 0.25 5.07 ± 0.21 5.53 ± 0.19
Data are presented as means ± SE. *p < 0.01 vs. sham.
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intestine. The estrogen receptor has been shown to be pre-
sent in the intestine,(3) and, recently, the newly cloned es-
trogen receptor-b has been identified in the upper gastro-
intestinal tract.(36) The precise downstream mechanisms by
which 17b-E2 may affect intestinal calcium absorption are
as yet purely speculative.
At kidney level, the reduction in 1,25(OH)2D3 levels af-
ter 17b-E2 suppletion is not reflected by a change in renal
calbindin 28K expression. Calbindin 28K is thought to play
a role in calcium uptake from the lumen by renal epithelial
cells,(37) and 1,25(OH)2D3 has been shown to regulate the
expression of calbindin 28K.(38) Potentially, at kidney level,
17b-E2 could compensate for the strong reduction in
1,25(OH)2D3 level independent of effects on VDR. It is
more likely that the lack of changes in calbindin 28K is
explained by the observation that the regulation of calbin-
din 28K gene expression may be more sensitive, under cer-
tain conditions, to changes in serum calcium levels than to
changes in serum 1,25(OH)2D3 levels.
(39–40) In our study,
no differences were observed in serum calcium levels as
well as urinary calcium excretion between the sham and
17b-E2–replete groups.
A marked observation in the present study was made
regarding the 1,25(OH)2D3 levels. Serum total
1,25(OH)2D3 levels were somewhat but not significantly
elevated following OVX. This is in agreement with earlier
observations in rats.(10,41) Nyomba et al. found increased
total serum 1,25(OH)2D3 levels but normal free serum
1,25(OH)2D3 levels following OVX because DBP levels
were also elevated.(42) In estrogen-deficient women, both
decreased(43,44) and normal serum 1,25(OH)2D3 lev-
els(20,45–47) have been reported. Major changes in serum
1,25(OH)2D3 levels were found with 17b-E2 supplementa-
tion. This resulted in a strong reduction of both total and
free serum 1,25(OH)2D3 levels. This observation is in line
with a study by Kalu et al.(10) in rats but appears to be in
contrast to the human situation. In women, transdermal
estrogen administration has no effect on either serum DBP
or serum 1,25(OH)2D3 levels
(41,48,49) or even an increase
with ethinyl estradiol was observed.(50) Therefore, our ob-
servations question whether the rat is a valid model for
understanding the human (patho)physiology of meno-
pause-related changes in vitamin D homeostasis. However,
the observed changes in intestinal calcium absorption are in
line with those observed in postmenopausal women.(18,20,30)
Also, several arguments have been put forward by others
that the OVX is a suitable model for postmenopausal os-
teoporosis.(51)
It is unlikely that the large changes in 1,25(OH)2D3 levels
can be explained by the relatively small decrease in serum
25(OH)D3 levels in the 17b-E2–replete group. As a conse-
quence, renal conversion of 25(OH)D3 into 1,25(OH)2D3
by 1a-hydroxylase should have been reduced and/or the
catabolism of 1,25(OH)2D3 and 25(OH)D3 should have
been increased. Because the estrogen receptor has been
demonstrated in the kidney,(1,52) 17b-E2 could directly in-
hibit 1a-hydroxylase activity and/or stimulate 24-
hydroxylase activity. With cultured opossum kidney cells, a
suppressive effect of 17b-E2 on 1a-hydroxylase activity has
been shown.(53) The present study is not conclusive as to
whether in the rat 17b-E2 inhibits 1a-hydroxylase activity
and/or induces 24-hydroxylase activity.
17b-E2 does not alter 1,25(OH)2D3 synthesis via a reduc-
tion of the potent stimulator of 1a-hydroxylase PTH (Table
2). However, 17b-E2 may have acted at the kidney to in-
hibit PTH-stimulated 1,25(OH)2D3 synthesis. In the litera-
ture, conflicting data are presented concerning the effect of
17b-E2 on serum PTH levels and 1a-hydroxylase activity.
Stock et al. have shown that 17b-E2 inhibits the PTH-
stimulated intracellular cAMP accumulation in opossum
kidney cells.(54) In laying hens, 17b-E2 reduces PTH recep-
tor binding affinity in calvaria and kidney.(55) However,
estrogen substitution in postmenopausal women may result
in either unchanged(19,49,54) or increased renal 1a-
hydroxylase activity, either due to increased serum PTH
levels(30) or an increased renal responsiveness to PTH.(56)
Furthermore, Ash et al. have shown in a rat model that
estrogens promote PTH-induced synthesis of calcitriol.(57)
Although the present data clearly demonstrate that 17b-
FIG. 1. Effects of OVX and OVX + 17b-E2 on calcium
flux in (A) duodenum and (B) jejunum. Calcium move-
ments were measured and calculated as described in the
Materials and Methods. Calcium influx is movement of cal-
cium from the intestinal lumen into the animal; calcium
efflux is movement of calcium from the animal into the
intestinal lumen; net calcium absorption is difference be-
tween calcium influx and calcium-efflux. Solid bars 4
sham-operated rats (n 4 8); hatched bars 4 ovariecto-
mized rats (n 4 8); open bars 4 OVX rats treated with
0.025 mg 17b-E2 (n 4 6); grey bars 4 OVX rats treated
with 0.05 mg 17b-E2 (n 4 8). Data are presented means ±
SE. *p < 0.05 and **p < 0.01 versus sham.
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E2 facilitates calcium absorption, the reduction in calcium
absorption after OVX could not be completely overcome
by 17b-E2 supplementation. Various factors, including gen-
eral anesthesia,(58) intraluminal pH(59) and glucose,(60,61)
and bile salt concentration(62) are known to affect intestinal
calcium transport. Therefore, calcium influx may have been
reduced, while calcium efflux remained unaffected, result-
ing in a negative calcium transport in the treated groups.
However, these factors are expected to have equal influ-
ence on calcium transport in the various groups. Therefore,
it is unlikely that they account for the differences among the
various groups. A more likely explanation is that 17b-E2
also enhances calcium transport in other parts of the intes-
tines. However, this seems not to be the case in the jeju-
num, because no significant differences in net calcium ab-
sorption among the various groups in this segment were
found. Another possibility is the cecum, which has been
shown to play an important role in calcium absorption in
rats(63,64) and which expresses the estrogen receptor.(3) An-
other explanation could be that in addition to estrogens,
other hormones or regulatory factors are reduced after
OVX, which are not restored after estrogen replacement.
In conclusion, the present study demonstrates that 17b-
E2 is positively involved in intestinal calcium absorption. In
addition, it provides results that 17b-E2 may have a direct
effect on intestinal calcium absorption independent of
1,25(OH)2D3. The reduction in 17b-E2 not only affects
bone metabolism but also directly affects calcium homeo-
stasis via effect on the intestine.
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